Beef Magazine is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Express® FP Provides More Modified-Live Protection For Pregnant Cows

The health of an unborn calf should never be gambled on, and no one can question the value of a pregnant female. That’s why producers have trusted protection from the Express® FP family of products for many years. Recently acquired label claims from this time-tested vaccine mean beef producers now have reassurance of its strong, long-lasting protection against key reproductive diseases and disease-induced losses.

Beginning in spring 2012, the Express FP family of vaccines will be labeled with three key new claims:

·      Aids in the prevention of abortion due to infectious bovine rhinotracheitis (IBR)

·      A demonstrated 12-month duration of immunity (DOI) against:

o   IBR-induced abortion

o   Bovine viral diarrhea (BVD) Types 1 and 2. This also includes protection against persistently infected (PI) calves caused by BVD           

·      Flexibility in vaccination with approval to administer to pregnant cattle provided they were vaccinated with any Express FP vaccine in the last 12 months according to label directions

“Protecting the reproductive health of the cow herd is so important for any successful cow-calf operation,” says Dr. Joe Campbell, Professional Services Veterinarian with Boehringer Ingelheim Vetmedica, Inc. “Express FP and its expanded label is one way we at Boehringer Ingelheim Vetmedica, Inc. are making a commitment to provide producers with tools to help prevent disease and help cattle perform to their highest potential.”

These new claims add to Express FP’s reputation as one of the most complete modified-live virus (MLV) reproductive vaccine families on the market. Backed by a solid foundation of research, Express FP vaccines are also labeled to:

·      Prevent PI calves caused by BVD Types 1 and 2

·      Prevent urinary shedding of Leptospira borgpetersenii serovarhardjo (typehardjo-bovis)

·      Aid in the prevention of respiratory disease caused by IBR virus, BVD Types 1 and 2, and bovine respiratory syncytial virus (BRSV)

·      Aid in the reduction of respiratory disease caused by parainfluenza 3 (PI3)

·      Aid in the reduction of infertility, delayed conception or abortion caused by Campylobacter fetus var. venerealis, and leptospirosis caused by five serovars of Leptospira.

“Express FP vaccines are exactly what producers are looking for in their herd health protocols,” Dr. Campbell says. “There are several combinations to fit your herd’s needs, and every vaccine is backed by a foundation of research and a label that spells out premier reproductive protection.”

For more information on Express FP products, contact your herd veterinarian, Boehringer Ingelheim Vetmedica, Inc. representative, or visit

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO) is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT, and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

For Boehringer Ingelheim — and its employees — carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.

In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24 percent of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit and follow us on Twitter at

For more information, please visit: